|
|
 |
|
Viewing report
|
|
|
|
Special Report: State of the Pharmaceutical Industry, 2009
Decision Resources, Inc., Feb 2009, Pages: 35
Change will be the only certainty in 2009 as economic reality dictates hard decisions and new approaches for the pharma industry. Disruptive change the kind that happens once in a couple of decades or longer can be healthy. It can motivate companies to move, kicking and screaming, away from the status quo to become streamlined, refocused businesses better able to succeed in future markets. This reality is not the hand the pharma industry wanted to be dealt, but the truth is that some companies will benefit from exploiting new opportunities and will become more competitive. In this report, we assess the new economic landscape and its likely impact on Big Pharma and biotech; the ongoing push for healthcare reform; the market outlook for Big Pharma, therapy areas, and biosimilars; insights into recent dealmaking trends/opportunities; and how companies can take advantage of recent advances in eHealth and eMarketing.
Get the Answers You Need to Shape Your Strategy
- 2008 brought a roller coaster ride to financial markets and economic instability around the world. As the new year opens, what is the current economic environment? How did the pharma and biotech industries fare on the 2008 stock market compared with other industries? How is venture capital investing expected to change in 2009?
- 2009 will be a testing time for the pharma industry as the 2008 global financial crisis begins to sting. What impacts can be expected? Is there a silver lining and what opportunities now exist? What is a sensible bifurcated strategy for the pharma industry in these troubling times?
- The U.S. people recognize a need for healthcare reform. What are the options released by the Congressional Budget Office in December 2008 for reducing federal healthcare spending? Which ones will impact the pharma industry? The health IT industry?
- Industry stakeholders recognize that the pharma industry is facing a difficult period. What significant changes do Decision Resources analysts forecast in the industry’s corporate landscape, therapy area landscape, and biosimilars market sector over the next five years?
- In 2007 and 2008, biotech companies achieved more leverage in negotiating deal terms. What factors influenced this trend and what can be expected in 2009? What advantages does competitive bidding afford the biotech partner? What factors result in an inflated perception of the real potential deal value? What advantages does a biotech partner seek in a new deal? A pharma partner?
- 2009’s financial turmoil will impact biotech-pharma partnering and M&As. What will be the impact of the economic crisis on biotech-pharma dealmaking? What exit strategies will investors likely seek? Which type of company will be a prime acquisition target?
- More than 60 million U.S. adults now use Health 2.0 content and services online and more than 20 million consumers post health content online. What are the commonly used Web 2.0 resources and how are consumers using them? What online resources exist for physicians and how are they using them? How can the pharma industry exploit advances in eHealth and eMarketing to their benefit?
Scope
- Economic crisis: global recession; Troubled Asset Relief Program (TARP); $787 billion economic stimulus package; American Recovery and Reinvestment Act of 2009; performance of pharma, biotech, and healthcare stock indices/exchange traded funds (EFTs); National Venture Capital Association third annual predictions survey, IPO window.
- Impact on the pharma industry: credit crunch, layoffs at the top 13 pharma companies, impact of unemployment on healthcare; 2008 pharma sales through retail pharmacies; size and growth rate of worldwide drug markets; 2008 Commonwealth Fund survey; problems with access to healthcare based on cost; toxic pricing environment; the silver lining; buying power of some Big Pharma; gap in available funding for start-ups with less mature healthcare technologies; value-for-money; new bifurcated strategy.
- Healthcare reform: cost-containment measures, Medicare price negotiations, drug reimportation, generics, biosimilars, comparative effectiveness research, cost-effectiveness data, Congressional Budget Office (CBO) report, near-universal health coverage, health information technology.
- Pharmaceutical market outlook: emerging markets, specialty therapy areas, biologics, diversification, biosimilars, Decision Resources Product view, top company rankings through 2014, victims of blockbuster patent expiries in need of resuscitative action, companies with better organic growth prospects, companies enjoying the greatest success, Merck BioVentures, companies most vulnerable to the biosimilars threat, companies facing significant, longer-term biosimilar challenges, patent expiry dates, anticipated biosimilars entry dates, Decision Resources Pharmaview, changing therapy area landscape, key growth areas, anemic growth in some therapy areas.
- Dealmaking trends and opportunities: 2007 and 2008 dealmaking trends, availability of capital, evolving biotech industry, factors that create leverage in negotiating new deals, perceived potential deal values, terms favorable to the biotech partner, interest in platform technologies, trends in M&As, change of control issues.
- eHealth and eMarketing opportunities: Direct-to-consumer advertising, most-visited eMarketing Web sites, Health 2.0 resources, health-related blogs, podcasting, message boards, chatrooms, posting health content online, online video, online patient groups, social networking, mergers in a fragmented market, online health information seeking by U.S. adults and physicians, targeted advertising, Manhattan Research’s study of 8,714 U.S. adults, Manhattan Research’s study of 1,832 practicing U.S. physicians, online video detailing, virtual conferences, physician service portals, mobile health (mHealth), drug reference databases.
Customers who bought this item also bought
The Pharmaceutical Industry 2008: Current and Future Trends and Strategic Issues Shaping Pharma
Drug Delivery Partnering Agreements in Pharma and Biotech
Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition
SPECIAL REPORT: Lessons Learned in the Pharma Industry, 2008
Mega-Mergers: Executing Change in the Pharma Industry
Biosimilars (2009 - 2014)
Royalty Financing Agreements in Pharma, Biotech and Diagnostics
Bio/Pharma R&D Statistical Sourcebook 2008/2009
The Indian Pharmaceutical Industry: Expansion & Ambitions + Indian Pharma Industry Tracker
eHealth Solutions for Pharma: Strategies for Salesforces, Marketing, Patient Compliance and Clinical Trials
Value-Added Pharma: How to Accomplish the Impossible
eHealth for the Pharmaceutical Industry: What Companies Need to Know about Trends in Physicians and Consumers Use of the Internet
|
|
|
|
